Official Title: “The Effect of Statins on the Urinary Proteome”

This study aims to investigate whether statines (rosuva- and pravastatin) induce tubular proteinuria.

Study Type: Interventional

Study Design: Diagnostic, Randomized, Double-Blind, Uncontrolled, Crossover Assignment, Safety Study

Study Primary Completion Date: October 2007

The proximal tubular cells of the kidney are responsible for reabsorption of proteins from the tubular lumen. In a study using Opossum kidney (OK) cells, receptor-mediated protein endocytosis was reduced by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, which are widely used for therapeutic reduction of plasma cholesterol levels (1).

In a subsequent in vitro study protein endocytosis in human mixed proximal/distal kidney tubular cells was investigated in the presence and absence of statins to explore the possible clinical relevance of the observations in OK cells (2). The uptake of FITC-labeled albumin in these cultures occurred selectively into proximal tubular cells while it was absent in distal tubular/collecting duct cells.

Three statins (simvastatin, pravastatin, and rosuvastatin) significantly inhibited the uptake of protein in a concentration-dependent way. This inhibitory effect of statins could be prevented by the co-addition of mevalonate, the product of HMG-CoA reductase. This effect was not the result of a statin-induced cytotoxicity since cell-viability was unaffected. These data suggest that statins have the potential to inhibit albumin uptake by the human proximal nephron as a result of inhibition of HMG-CoA reductase in the proximal tubule cells. A reduced prenylation of some proteins critically involved in endocytosis has been put forward as the underlying mechanism. Knowing these data it has been suggested that the occurrence of proteinuria in some patients treated with high statin doses is the result of a reduced tubular reabsorption/endocytosis of normally filtered proteins. To further explore the clinical relevance of such a mechanism, the composition of the urinary proteome under statin treatment will be investigated in normal healthy volunteers by two-dimensional gel electrophoresis based proteomics analysis.

Intervention(s) in this Clinical Trial

• Drug: Rosuvastatin-Crestor
• Drug: Pravastatin-Pravasine

Primary Measures

• The urinary protein pattern observed by difference gel electrophoresis based proteomics analysis in healthy subjects before and after the administration of rosuvastatin (Crestor®).

Secondary Measures

• The urinary protein pattern observed by difference gel electrophoresis based proteomics analysis in healthy subjects before and during the administration of pravastatin (Pravasine®).
• The urinary protein pattern observed by difference gel electrophoresis based proteomics analysis in healthy subjects during the administration of rosuvastatin (Crestor®) vs pravastatin (Pravasine®).
• The urinary protein pattern observed by difference gel electrophoresis based proteomics analysis in healthy subjects during the administration of rosuvastatin (Crestor®) or pravastatin (Pravasine®) and after wash-out of these compounds.
• The urinary albumin and retinol binding protein concentration before in healthy subjects, during and after administration of rosuvastatin (Crestor®) or pravastatin (Pravasine®).

Inclusion Criteria:

• Male, age range: 25 - 65 years
• Non-smoker
• Proteinuria: < 60 mg/24 hours
• Dipstick negative hematuria
• Bloodpressure: < 135 mm systolic, < 85 mm dyastolic
• Waist circumference: < 94 cm

Exclusion Criteria:

• Treatment with lipid-lowering drugs <1 year prior to the study
• Known history of diabetes or fasting glucose level: < 110 mg/dl
• Anti-hypertensive medication
• Life-expectancy < 1 year
• Pharmacological treatment with inotropes
• Acute or chronic inflammatory process, use if anti-inflammatory drugs or immunosuppression
• Clinically active malignant disease
• Administration of any investigational drug within 30 days preceding study start and during the study
• Known intolerance to rosuvastatin or other statins
• Acute or chronic liver disease or ALAT>2.0 x upper limit of normal (ULN) at enrolment visit.
• Chronic muscle disease such as dermatomyositis or polymyositis or unexplained creatinine kinase (CK) above 3 x ULN at enrolment.
• Uncontrolled hypothyroidism as indicated by a thyroid stimulating hormone (TSH) > 2 x
• ULN at enrolment.
• Renal insufficiency: creatinine > 2.0mg/dl
• Known or suspect alcohol or drug abuse.

Gender Eligibility for this Clinical Trial: Male

Minimum Age for this Clinical Trial: 25 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Lead Sponsor: Universiteit Antwerpen

Overall Clinical Trial Officials and Contacts

Patrick C D'Haese, Prof Study Director Universiteit Antwerpen  

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00464503

Study ID Number: STAT-AZ-01

ClinicalTrials.gov Identifier: NCT00464503

Health Authority: Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment